#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients


Autoři: Yusuke Tomita aff001;  Kazuhiro Iwadoh aff001;  Yuichi Ogawa aff001;  Katsuyuki Miki aff001;  Yojiro Kato aff001;  Kotaro Kai aff001;  Akihito Sannomiya aff001;  Ichiro Koyama aff001;  Kumiko Kitajima aff001;  Ichiro Nakajima aff001;  Shohei Fuchinoue aff001
Působiště autorů: Department of Surgery, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan aff001
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0224203

Souhrn

This study was conducted to evaluate de novo donor-specific anti-human leukocyte antigen (HLA) antibody (dnDSA) production leading to antibody-mediated rejection (ABMR) after rituximab induction in non-sensitized ABO-compatible living kidney transplantation (ABO-CLKTx). During 2008–2015, 318 ABO-CLKTx were performed at the Department of Surgery III at Tokyo Women’s Medical University Hospital. To reduce confounding factors, we adopted a propensity score analysis, which was applied with adjustment for age, gender, duration of pretransplant dialysis, HLA mismatch count, preformed DSA, non-insulin-dependent diabetes mellitus, immunosuppressive treatment, and estimated glomerular filtration rate (eGFR) on postoperative day 7. Using a propensity score matching model (1 : 1, 115 pairs), we analyzed the long-term outcomes of 230 ABO-CLKTx recipients retrospectively. Recipients were classified into a rituximab-treated (RTX-KTx, N = 115) group and a control group not treated with rituximab (C-KTx, N = 115). During five years, adverse events, survival rates for grafts and patients, and incidence of biopsy-proven acute rejection (BPAR) and dnDSA production for the two groups were monitored and compared. All recipients in the RTX-KTx group received rituximab induction on preoperative day 4 at a single fixed low dose of 100 mg; the CD19+ B cells were eliminated completely before surgery. Of those recipients, 13 (11.3%) developed BPAR; 1 (0.8%) experienced graft loss. By contrast, of C-KTx group recipients, 25 (21.7%) developed BPAR; 3 (2.6%) experienced graft loss. The RTX-KTx group exhibited a significantly lower incidence of BPAR (P = .041) and dnDSA production (13.9% in the RTX-KTx group vs. 26.9% in the C-RTx group, P = .005). Furthermore, lower incidence of CMV infection was detected in the RTX-KTx group than in the C-KTx group (13.9% in the RTX-KTx group vs. 27.0% in the C-KTx group, P = .014). No significant difference was found between groups for several other factors: renal function (P = .384), graft and patient survival (P = .458 and P = .119, respectively), and the respective incidences of BK virus infection (P = .722) and leukopenia (P = .207). During five-year follow-up, single fixed low-dose rituximab therapy is sufficient for ensuring safety, reducing rejection, and suppressing dnDSA production for immunological low-risk non-sensitized ABO-CLKTx.

Klíčová slova:

B cells – Flow cytometry – Graft survival – Immune suppression – Inflammation – Kidneys – Renal transplantation – T cells


Zdroje

1. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002;74(9):1207–10. doi: 10.1097/00007890-200211150-00001 12451255.

2. Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant. 2004;18(3):254–60. doi: 10.1111/j.1399-0012.2004.00151.x 15142045.

3. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005;5(1):145–8. doi: 10.1111/j.1600-6143.2004.00653.x 15636623.

4. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol. 2009;162 : 61–74. Epub 2008/10/31. doi: 10.1159/000170813 19001814.

5. Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation. 2011;91(8):853–7. doi: 10.1097/TP.0b013e31820f08e8 21297552.

6. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7(4):864–71. doi: 10.1111/j.1600-6143.2006.01711.x 17391129.

7. Gloor JM, Sethi S, Stegall MD, Park WD, Moore SB, DeGoey S et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant. 2007;7(9):2124–32. Epub 2007/07/03. doi: 10.1111/j.1600-6143.2007.01895.x 17608832.

8. Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med. 2018;379(12):1150–60. doi: 10.1056/NEJMra1802677 30231232.

9. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95. 9310469.

10. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6(10):2418–28. Epub 2006/08/21. doi: 10.1111/j.1600-6143.2006.01497.x 16925569.

11. Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233–41. Epub 2012/01/17. doi: 10.1007/s00262-011-1168-2 22249775.

12. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant. 2012;12(2):469–76. Epub 2011/11/04. doi: 10.1111/j.1600-6143.2011.03830.x 22054413.

13. Zhang R. Donor-Specific Antibodies in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017. Epub 2017/04/26. doi: 10.2215/CJN.00700117 28446536.

14. Castro A, Malheiro J, Tafulo S, Dias L, Martins LS, Fonseca I et al. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study. HLA. 2017;90(5):267–75. Epub 2017/08/24. doi: 10.1111/tan.13111 28776960.

15. Heilman RL, Nijim A, Desmarteau YM, Khamash H, Pando MJ, Smith ML et al. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation. 2014;98(12):1310–5. doi: 10.1097/TP.0000000000000216 24879384.

16. Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015;15(11):2921–30. Epub 2015/06/10. doi: 10.1111/ajt.13347 26096305.

17. Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N et al. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury. Transplantation. 2016;100(10):2194–202. doi: 10.1097/TP.0000000000001012 26636737.

18. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398–406. Epub 2010/07/15. doi: 10.1681/ASN.2009101065 20634297.

19. Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009;87(9):1325–9. doi: 10.1097/TP.0b013e3181a235fd 19424032.

20. Tydén G, Ekberg H, Tufveson G, Mjörnstedt L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation. 2012;94(3):e21–2. doi: 10.1097/01.tp.0000418580.88642.e1 22872297.

21. van den Hoogen MW, Kamburova EG, Baas MC, Steenbergen EJ, Florquin S M Koenen HJ et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant. 2015;15(2):407–16. doi: 10.1111/ajt.13052 25612493.

22. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant. 2017;17(1):28–41. doi: 10.1111/ajt.14107 27862883.

23. Cherkassky L, Lanning M, Lalli PN, Czerr J, Siegel H, Danziger-Isakov L et al. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant. 2011;11(7):1388–96. Epub 2011/05/12. doi: 10.1111/j.1600-6143.2011.03540.x 21564525.

24. Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;(1):CD003897. Epub 2010/01/20. doi: 10.1002/14651858.CD003897.pub3 20091551.

25. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol. 1997;8(11):1771–7. 9355081.

26. Tomita Y, Tojimbara T, Iwadoh K, Nakajima I, Fuchinoue S. Outcomes of Kidney Transplantation from Circulatory Death Donors With Increased Terminal Creatinine Levels in Serum. Transplantation. 2016;100(7):1532–40. doi: 10.1097/TP.0000000000000955 26479288.

27. Tomita Y, Iwadoh K, Ogawa Y, Miki K, Kai K, Sannomiya A et al. Single Graft utilization From Donors With Severe Acute Kidney Injury After Circulatory Death. Transplant Direct. 2018;4(4):e355. Epub 2018/03/19. doi: 10.1097/TXD.0000000000000768 29707626.

28. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004;4(3):438–43. 14961999.

29. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation. 2010;89(12):1466–70. doi: 10.1097/TP.0b013e3181dc0999 20559108.

30. D’Addio F, Boenisch O, Magee CN, Yeung MY, Yuan X, Mfarrej B et al. Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PLoS One. 2013;8(1):e53797. Epub 2013/01/10. doi: 10.1371/journal.pone.0053797 23326509.

31. Carvello M, Petrelli A, Vergani A, Lee KM, Tezza S, Chin M et al. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo -⁠ and autoimmune responses. Diabetes. 2012;61(1):155–65. Epub 2011/11/10. doi: 10.2337/db11-0684 22076927.

32. Schröder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12(1):19–28. doi: 10.1016/S0966-3274(03)00059-5 14551029.

33. Kamburova EG, Koenen HJ, van den Hoogen MW, Baas MC, Joosten I, Hilbrands LB. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS One. 2014;9(11):e112658. Epub 2014/11/13. doi: 10.1371/journal.pone.0112658 25393622.

34. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4(8):1357–60. doi: 10.1111/j.1600-6143.2004.00502.x 15268740.

35. Joosten I, Baas MC, Kamburova EG, van den Hoogen MW, Koenen HJ, Hilbrands LB. Anti-B cell therapy with rituximab as induction therapy in renal transplantation. Transpl Immunol. 2014;31(4):207–9. Epub 2014/09/28. doi: 10.1016/j.trim.2014.09.011 25270152.

36. van den Hoogen MW, Steenbergen EJ, Baas MC, Florquin S, Hilbrands LB. Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome. Transplant Direct. 2017;3(4):e143. Epub 2017/03/10. doi: 10.1097/TXD.0000000000000659 28405599.

37. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant. 2010;10(1):89–98. Epub 2009/07/28. doi: 10.1111/j.1600-6143.2009.02785.x 19656128.

38. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109(8):830–40. Epub 2011/08/25. doi: 10.1161/CIRCRESAHA.111.248542 21868694.


Článek vyšel v časopise

PLOS One


2019 Číslo 10
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

BONE ACADEMY 2025
nový kurz
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#